Boothbay Fund Management LLC Increases Position in Mineralys Therapeutics, Inc. $MLYS

Boothbay Fund Management LLC boosted its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 15.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 942,626 shares of the company’s stock after purchasing an additional 125,700 shares during the period. Mineralys Therapeutics makes up about 0.5% of Boothbay Fund Management LLC’s portfolio, making the stock its 5th largest holding. Boothbay Fund Management LLC owned 1.19% of Mineralys Therapeutics worth $35,744,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Alliancebernstein L.P. increased its position in shares of Mineralys Therapeutics by 3,160.1% during the 3rd quarter. Alliancebernstein L.P. now owns 882,415 shares of the company’s stock valued at $33,461,000 after purchasing an additional 855,348 shares during the period. Orbimed Advisors LLC bought a new position in Mineralys Therapeutics during the second quarter valued at about $10,288,000. Stempoint Capital LP boosted its stake in Mineralys Therapeutics by 605.3% during the second quarter. Stempoint Capital LP now owns 631,586 shares of the company’s stock valued at $8,551,000 after buying an additional 756,586 shares in the last quarter. Caligan Partners LP grew its holdings in Mineralys Therapeutics by 37.4% during the third quarter. Caligan Partners LP now owns 2,772,654 shares of the company’s stock worth $105,139,000 after acquiring an additional 755,302 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Mineralys Therapeutics by 29.8% during the third quarter. Vanguard Group Inc. now owns 3,018,999 shares of the company’s stock worth $114,480,000 after acquiring an additional 692,550 shares during the period. 84.46% of the stock is owned by institutional investors.

Mineralys Therapeutics Trading Down 3.0%

Shares of MLYS opened at $26.19 on Friday. The business’s 50-day moving average price is $30.45 and its 200 day moving average price is $35.51. The stock has a market capitalization of $2.07 billion, a P/E ratio of -11.05 and a beta of 0.57. Mineralys Therapeutics, Inc. has a 1-year low of $10.44 and a 1-year high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. On average, research analysts predict that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Insider Activity at Mineralys Therapeutics

In related news, CFO Adam Scott Levy sold 10,758 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $32.14, for a total value of $345,762.12. Following the completion of the transaction, the chief financial officer owned 8,638 shares of the company’s stock, valued at approximately $277,625.32. This trade represents a 55.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $26.84, for a total transaction of $58,269.64. Following the transaction, the insider owned 82,489 shares in the company, valued at approximately $2,214,004.76. The trade was a 2.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 342,919 shares of company stock worth $11,755,439. 25.56% of the stock is owned by corporate insiders.

Mineralys Therapeutics News Summary

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: NDA accepted by FDA and PDUFA set (Dec. 22, 2026) for lorundrostat — formal regulatory review underway, which de-risks timing for potential approval and commercialization. GlobeNewswire: Q4 results & NDA acceptance
• Positive Sentiment: Q4 results surprised to the upside — reported EPS of ($0.40) vs. consensus ($0.57), suggesting operational execution beat expectations and reducing near-term downside to estimates. MarketBeat: Q4 earnings summary
• Positive Sentiment: Management is actively preparing for launch and payer engagement ahead of the regulatory decision — signaling commercialization planning and market-access work that could speed uptake if approved. Seeking Alpha: Launch & payer engagement
• Neutral Sentiment: Conference call and transcript provide management’s roadmap and data context (Q4 call reviewed NDA strategy, clinical data and next steps); useful for modeling but not a surprise item. Seeking Alpha: Earnings call transcript
• Neutral Sentiment: Press coverage highlights steady progress with FDA interactions and public messaging; these articles reiterate facts rather than deliver new catalysts. Yahoo Finance: FDA progress TipRanks: NDA acceptance overview
• Negative Sentiment: Critical commentary warns of potential interference from larger pharma interests that could complicate the approval or market dynamics — introduces regulatory and competitive risk that can pressure shares. Seeking Alpha: Concerns over big pharma pressure

Analyst Ratings Changes

A number of brokerages have weighed in on MLYS. Stifel Nicolaus upped their price target on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, December 19th. Wall Street Zen raised shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Jefferies Financial Group reiterated a “hold” rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a report on Friday. Bank of America increased their target price on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research note on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Mineralys Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $49.14.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.